Monitor the ASCO presentations in late May–early June 2026 for data quality and response rates, which could catalyze stock movement. Positive data may attract partnership interest, especially for IMA401 and the GEN2 platform.
Price Chart
Executive Summary
Immatics announced that four abstracts from its clinical programs will be presented as oral presentations at the 2026 ASCO Annual Meeting, including Phase 1b data for anzu-cel in melanoma, updated data for IMA203CD8 in gynecologic cancers, and first-in-human results for IMA401. This confirms scientific validation and visibility for its PRAME and MAGEA4/8-targeted therapies.
Key Facts
- Four oral presentations accepted at ASCO 2026, a top oncology conference
- Data includes Phase 1b results for anzu-cel in advanced melanoma and uveal melanoma
- Updated Phase 1a/1b data for IMA203CD8 (GEN2) in gynecologic cancers
- Updated Phase 1 data for PRAME cell therapy in synovial sarcoma
- First-in-human results for IMA401, a MAGEA4/8 bispecific, across multiple solid tumors
Financial Impact
No direct financial impact disclosed; potential for increased investor and partnership interest due to high-profile data presentation
Risk Factors
- Clinical data remains preliminary and subject to verification
- No guarantee of regulatory or commercial success despite presentation acceptance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0000950103-26-005970 |
| Document: dp245406_6k.htm | 0000950103-26-005970 |
| Document: 0000950103-26-005970-index-headers.html | 0000950103-26-005970 |
| Document: 0000950103-26-005970-index.html | 0000950103-26-005970 |
| Document: 0000950103-26-005970.txt | 0000950103-26-005970 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.45 $8.50 | ▼ −10.05% | ▼ −10.31% | $7.59 (−19.68%) |
Aug 26, 2026 5w ago | 6-K | $9.36 $8.33 | ▲ +11.00% | ▲ +10.50% | $7.59 (+18.91%) |
Aug 18, 2026 6w ago | 6-K | $9.09 $8.82 | ▼ −2.97% | ▼ −1.98% | $7.59 (−16.50%) |
Aug 18, 2026 6w ago | Press Release | $9.09 $8.82 | ▼ −2.97% | ▼ −1.98% | $7.59 (−16.50%) |
Jun 2, 2026 17w ago | 6-K | $10.04 $9.85 | ▼ −1.89% | ▼ −0.33% | $7.59 (−24.40%) |
Jun 1, 2026 17w ago | 6-K | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
Jun 1, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
May 31, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
May 30, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
May 12, 2026 20w ago | 6-K | $11.39 $8.87 | ▲ +22.12% | ▲ +20.40% | $7.59 (+33.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access